CBD Global Sciences Inc. engages in cannabidiol (CBD) farming, processing, and product manufacturing business. More Details
+ 2 more risks
Imperfect balance sheet with weak fundamentals.
Share Price & News
How has CBD Global Sciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CBDN's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: CBDN underperformed the Canadian Pharmaceuticals industry which returned -17.2% over the past year.
Return vs Market: CBDN exceeded the Canadian Market which returned -60.7% over the past year.
Price Volatility Vs. Market
How volatile is CBD Global Sciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
Is CBD Global Sciences undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether CBD Global Sciences is trading at an attractive price based on the cash flow it is expected to produce in the future. But as CBD Global Sciences has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
- Take a look at our analysis of CBDN's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through CBD Global Sciences regulatory filings.
- Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.
How is CBD Global Sciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CBD Global Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of CBDN’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- CBD Global Sciences competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has CBD Global Sciences performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: CBDN is currently unprofitable.
Growing Profit Margin: CBDN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if CBDN's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare CBDN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CBDN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (30.9%).
Return on Equity
High ROE: CBDN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is CBD Global Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: CBDN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: CBDN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: CBDN has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: CBDN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CBDN has sufficient cash runway for 0 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: CBDN is forecast to have sufficient cash runway for 0 months based on free cash flow estimates, but has since raised additional capital.
What is CBD Global Sciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CBDN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CBDN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CBDN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CBDN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CBDN's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Brad Wyatt (51 yo)
Mr. Brad Wyatt is a Co-Founder of CBD Global Sciences Inc. and also serves as its Chief Executive Officer, President and Director. Mr. Wyatt served as Chief Executive Officer, President, and Executive Dire ...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.4%.
CBD Global Sciences Inc.'s company bio, employee growth, exchange listings and data sources
- Name: CBD Global Sciences Inc.
- Ticker: CBDN
- Exchange: CNSX
- Founded: 2018
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$5.137m
- Shares outstanding: 34.24m
- Website: https://www.cbdglobalsciences.com
- CBD Global Sciences Inc.
- 225 Union Boulevard
- Suite 350
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CBDN||CNSX (Canadian National Stock Exchange)||Yes||Common Shares||CA||CAD||Oct 2019|
|GS3||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Oct 2019|
|CBDN.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Oct 2019|
CBD Global Sciences Inc. engages in cannabidiol (CBD) farming, processing, and product manufacturing business. It offers provides biomass, CBD oil, and CBD oil products under the Aethics, CannaOil, and Str ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/31 01:04|
|End of Day Share Price||2020/10/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.